Kush Parmar - 14 Jun 2022 Form 4 Insider Report for Vor Biopharma Inc. (VOR)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: VOR
Reported as of: 14 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Jun 2022, 17:09:59 UTC
Prior SEC filing: 07 Jun 2022
Next SEC filing: 17 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Rich Segal, Attorney-in-Fact

Key filing fact

Kush Parmar filed Form 4 for Vor Biopharma Inc. (VOR) on 16 Jun 2022.

Key facts

This page summarizes Kush Parmar's Form 4 filing for Vor Biopharma Inc. (VOR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Jun 2022, 17:09.

Change

Previous filing in this sequence was filed on 07 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VOR transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +16,911
Change %
Price: $0.000000
Shares after: 16,911
Date: 14 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,911
Exercise price: $4.26
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.